These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37218555)

  • 1. Improvement of clinical and radiological manifestations of coxitis in patients with ankylosing spondylitis treated with tumor necrosis factor-α inhibitor golimumab: Results of a 24-Month prospective observation study (GO-COX Study).
    Erdes S; Agafonova EM; Timokhina DG; Davidian SY; Zemerova EV; Kulikov AI; Markova OG; Achikyan VF
    Int J Rheum Dis; 2023 Jul; 26(7):1321-1329. PubMed ID: 37218555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey.
    Lopalco G; Venerito V; Cantarini L; Emmi G; Salaffi F; Di Carlo M; Tafuri S; Gentileschi S; Di Scala G; Nivuori M; Cacciapaglia F; Galeazzi M; Lapadula G; Iannone F
    Clin Exp Rheumatol; 2019; 37(5):762-767. PubMed ID: 31025925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study.
    Inman RD; Baraliakos X; Hermann KA; Braun J; Deodhar A; van der Heijde D; Xu S; Hsu B
    Arthritis Res Ther; 2016 Dec; 18(1):304. PubMed ID: 28031053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associated Factors with the Severity of Hip Involvement in Spondyloarthritis and Efficacy of TNF α Inhibitors in these Patients.
    Slouma M; Rahmouni S; Dhahri R; Cheour E; Gharsallah I; Metoui L; Louzir B
    Curr Rheumatol Rev; 2022; 18(1):58-63. PubMed ID: 34636315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced Occurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis Treated with Golimumab - The GO-EASY Study.
    van Bentum RE; Heslinga SC; Nurmohamed MT; Gerards AH; Griep EN; Koehorst CBJM; Kok MR; Schilder AM; Verhoef M; van der Horst-Bruinsma IE
    J Rheumatol; 2019 Feb; 46(2):153-159. PubMed ID: 30385705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained low functional impairment in axial spondyloarthritis (axSpA): which are the primary outcomes that should be targeted to achieve this?
    Maksymowych WP; Inman RD; Bessette L; Rahman P; Rampakakis E; Asin-Milan O; Rachich M; Marrache AM; Lehman AJ
    Arthritis Res Ther; 2023 Apr; 25(1):70. PubMed ID: 37118833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Change in MRI in patients with spondyloarthritis treated with anti-TNF agents: systematic review of the literature and meta-analysis.
    Khoury G; Combe B; Morel J; Lukas C
    Clin Exp Rheumatol; 2021; 39(2):242-252. PubMed ID: 33506749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment efficacy of etanercept and MTX combination therapy for ankylosing spondylitis hip joint lesion in Chinese population.
    Lian F; Yang X; Liang L; Xu H; Zhan Z; Qiu Q; Ye Y
    Rheumatol Int; 2012 Jun; 32(6):1663-7. PubMed ID: 21387110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low BASDAI score alone is not a good predictor of anti-tumor necrosis factor treatment efficacy in ankylosing spondylitis: a retrospective cohort study.
    Nam B; Koo BS; Lee TH; Shin JH; Kim JJ; Lee S; Joo KB; Kim TH
    BMC Musculoskelet Disord; 2021 Feb; 22(1):140. PubMed ID: 33541326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Although female patients with ankylosing spondylitis score worse on disease activity than male patients and improvement in disease activity is comparable, male patients show more radiographic progression during treatment with TNF-α inhibitors.
    van der Slik B; Spoorenberg A; Wink F; Bos R; Bootsma H; Maas F; Arends S
    Semin Arthritis Rheum; 2019 Apr; 48(5):828-833. PubMed ID: 30253878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease Activity Cutoff Values in Initiating Tumor Necrosis Factor Inhibitor Therapy in Ankylosing Spondylitis: A German GO-NICE Study Subanalysis.
    Braun J; Baraliakos X; Kiltz U; Krüger K; Burmester GR; Wassenberg S; Thomas MH
    J Rheumatol; 2020 Jan; 47(1):35-41. PubMed ID: 30877206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of extra-articular manifestations on tumor necrosis factor-α inhibitor treatment duration in patients with ankylosing spondylitis: nationwide data from the Korean College of Rheumatology BIOlogics (KOBIO) registry.
    Kim Y; Park S; Kim HS
    Clin Rheumatol; 2018 Dec; 37(12):3275-3284. PubMed ID: 30251059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Propensity score matching/reweighting analysis comparing intravenous golimumab to infliximab for ankylosing spondylitis using data from the GO-ALIVE and ASSERT trials.
    Gensler LS; Chakravarty SD; Cameron C; Peterson S; Spin P; Kafka S; Nair S; Deodhar A
    Clin Rheumatol; 2020 Oct; 39(10):2907-2917. PubMed ID: 32367407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors.
    Pedersen SJ; Sørensen IJ; Hermann KG; Madsen OR; Tvede N; Hansen MS; Thamsborg G; Andersen LS; Majgaard O; Loft AG; Erlendsson J; Asmussen K; Johansen JS; Jurik AG; Møller J; Hasselquist M; Mikkelsen D; Skjødt T; Hansen A; Ostergaard M
    Ann Rheum Dis; 2010 Jun; 69(6):1065-71. PubMed ID: 19740906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of hip involvement in patients with ankylosing spondylitis: reliability and validity of the Hip Inflammation MRI Scoring System.
    Man S; Zhang L; Bian T; Li H; Ma Z; Zhou Y
    BMC Musculoskelet Disord; 2021 Aug; 22(1):705. PubMed ID: 34404369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.
    Arends S; Brouwer E; van der Veer E; Groen H; Leijsma MK; Houtman PM; Th A Jansen TL; Kallenberg CG; Spoorenberg A
    Arthritis Res Ther; 2011 Jun; 13(3):R94. PubMed ID: 21689401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physical Function and Spinal Mobility Remain Stable Despite Radiographic Spinal Progression in Patients with Ankylosing Spondylitis Treated with TNF-α Inhibitors for Up to 10 Years.
    Poddubnyy D; Fedorova A; Listing J; Haibel H; Baraliakos X; Braun J; Sieper J
    J Rheumatol; 2016 Dec; 43(12):2142-2148. PubMed ID: 27803139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-steroidal anti-inflammatory drugs in patients with stable ankylosing spondylitis receiving tumor necrosis factor inhibitor: continued vs withdrawn.
    Park JH; Kwon OC; Park MC
    Clin Rheumatol; 2020 Dec; 39(12):3669-3675. PubMed ID: 32447601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous Improvement of Physical Functioning in Ankylosing Spondylitis Patients by Tumor Necrosis Factor Inhibitors: Three-Year Followup and Predictors.
    van Weely SF; Kneepkens EL; Nurmohamed MT; Dekker J; van der Horst-Bruinsma IE
    Arthritis Care Res (Hoboken); 2016 Oct; 68(10):1522-9. PubMed ID: 26881893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Procollagen I N-terminal peptide correlates with inflammation on sacroiliac joint magnetic resonance imaging in ankylosing spondylitis but not in non-radiographic axial spondyloarthritis: A cross-sectional study.
    Li X; Liang A; Chen Y; Lam NS; Long X; Xu X; Zhong S
    Mod Rheumatol; 2022 Jul; 32(4):770-775. PubMed ID: 34897520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.